Novocure Ltd. (NVCR)

43.87
1.30 2.90
NASDAQ : Health Technology
Prev Close 45.17
Open 45.24
Day Low/High 43.61 / 45.72
52 Wk Low/High 16.10 / 53.70
Volume 173.37K
Avg Volume 778.10K
Exchange NASDAQ
Shares Outstanding 92.90M
Market Cap 4.08B
EPS -0.70
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Novocure To Report Third Quarter 2018 Financial Results

Novocure To Report Third Quarter 2018 Financial Results

Novocure (NASDAQ: NVCR) announced today that it will report financial results for the third quarter 2018 on Thursday, October 25, 2018, before the U.

Data From STELLAR Registration Trial Of Tumor Treating Fields In Mesothelioma To Be Presented At The IASLC 19th World Conference On Lung Cancer

Data From STELLAR Registration Trial Of Tumor Treating Fields In Mesothelioma To Be Presented At The IASLC 19th World Conference On Lung Cancer

Novocure (NASDAQ: NVCR) announced today that results from its STELLAR phase 2 registration trial in mesothelioma will be highlighted in an oral presentation at the IASLC 19th World Conference on Lung Cancer hosted by the International Association for the...

Novocure And Zai Lab Announce Strategic Collaboration With A License Agreement For Tumor Treating Fields In Greater China

Novocure And Zai Lab Announce Strategic Collaboration With A License Agreement For Tumor Treating Fields In Greater China

Novocure (NASDAQ:NVCR), a global oncology company developing a proprietary platform technology called Tumor Treating Fields, and Zai Lab (NASDAQ:ZLAB), a Shanghai-based innovative biopharmaceutical company, announced today an exclusive license agreement...

Tumor Treating Fields Plus Standard Of Care Chemotherapy Significantly Extends Median Overall Survival By 6.1 Months In STELLAR Phase 2 Registration Trial In Mesothelioma Compared To Historical Control

Tumor Treating Fields Plus Standard Of Care Chemotherapy Significantly Extends Median Overall Survival By 6.1 Months In STELLAR Phase 2 Registration Trial In Mesothelioma Compared To Historical Control

Novocure (NASDAQ: NVCR) announced final results from its STELLAR phase 2 registration trial in mesothelioma, demonstrating a significant extension in median overall survival among patients treated with Tumor Treating Fields plus standard of care...

Novocure And US Oncology Research Announce Collaboration On PANOVA-3 Trial For Patients With Advanced Pancreatic Cancer

Novocure And US Oncology Research Announce Collaboration On PANOVA-3 Trial For Patients With Advanced Pancreatic Cancer

Novocure (NASDAQ: NVCR) and US Oncology Research are collaborating on PANOVA-3, a phase 3 pivotal trial testing the efficacy of Tumor Treating Fields combined with nab-paclitaxel and gemcitabine in patients with unresectable locally advanced pancreatic...

Novocure To Present At Two Upcoming Investor Conferences

Novocure To Present At Two Upcoming Investor Conferences

Novocure (NASDAQ:NVCR) announced today that it will participate in two upcoming investor conferences.

Novocure Announces Addition To Its Board Of Directors

Novocure Announces Addition To Its Board Of Directors

Novocure (NASDAQ: NVCR) has announced an addition to its board of directors. Jeryl (Jeri) Hilleman, an experienced executive leader, was elected to Novocure's board in July 2018.

Gynecologic Oncology Publishes Results Of The INNOVATE Phase 2 Pilot Study Demonstrating Combination Of Tumor Treating Fields With Paclitaxel May Improve Survival Of Patients With Recurrent Ovarian Cancer

Gynecologic Oncology Publishes Results Of The INNOVATE Phase 2 Pilot Study Demonstrating Combination Of Tumor Treating Fields With Paclitaxel May Improve Survival Of Patients With Recurrent Ovarian Cancer

Novocure (NASDAQ: NVCR) announced today that the results of its INNOVATE phase 2 pilot trial have been published in Gynecologic Oncology.

Novocure Reports Second Quarter 2018 Financial Results And Provides Company Update

Novocure Reports Second Quarter 2018 Financial Results And Provides Company Update

Novocure (NASDAQ:NVCR) today reported financial results for the three and six months ended June 30, 2018.

Interesting NVCR Put And Call Options For March 2019

Interesting NVCR Put And Call Options For March 2019

Investors in NovoCure Ltd saw new options become available this week, for the March 2019 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 233 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Novocure Announces 13 Presentations At American Society For Radiation Oncology 2018 Annual Meeting

Novocure Announces 13 Presentations At American Society For Radiation Oncology 2018 Annual Meeting

Novocure (NASDAQ: NVCR) announced today 13 presentations on Tumor Treating Fields at the American Society for Radiation Oncology (ASTRO) 2018 Annual Meeting, Oct.

Scientific Track Dedicated To Tumor Treating Fields At 40th International Conference Of The IEEE Engineering In Medicine And Biology Society

Scientific Track Dedicated To Tumor Treating Fields At 40th International Conference Of The IEEE Engineering In Medicine And Biology Society

Novocure (NASDAQ: NVCR) announced today that a scientific track has been dedicated to Tumor Treating Fields at the 40 th International Conference of the IEEE Engineering in Medicine and Biology Society (EMBS), July 17 through July 21 in Honolulu, Hawaii.

Novocure Appoints Pritesh Shah As Chief Commercial Officer

Novocure Appoints Pritesh Shah As Chief Commercial Officer

Novocure (NASDAQ:NVCR) announced today that Pritesh Shah has been appointed as Novocure's Chief Commercial Officer, reporting to Novocure's Chief Executive Officer Asaf Danziger.

Novocure To Report Second Quarter 2018 Financial Results

Novocure To Report Second Quarter 2018 Financial Results

Novocure (NASDAQ: NVCR) announced today that it will report financial results for the second quarter 2018 on Thursday, July 26, 2018, before the U.

NovoCure's Charts Look Bullish

NovoCure's Charts Look Bullish

NovoCure started a strong rally in 2017 and continues to move up.

Under Armour, Cognex, Novocure: 'Mad Money' Lightning Round

Under Armour, Cognex, Novocure: 'Mad Money' Lightning Round

Jim Cramer weighs in on Under Armour, Cognex, Novocure, FireEye, Weight Watchers, Bristol-Meyers Squibb and Chegg.

The Name of the Game Is Growth: Cramer's 'Mad Money' Recap (Wednesday 6/20/18)

The Name of the Game Is Growth: Cramer's 'Mad Money' Recap (Wednesday 6/20/18)

Jim Cramer explains why the fulcrum for the financial markets is growth -- not tariffs, or the Fed, or interest rates.

NVCR Crosses Above Average Analyst Target

NVCR Crosses Above Average Analyst Target

In recent trading, shares of NovoCure Ltd have crossed above the average analyst 12-month target price of $31.80, changing hands for $31.95/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Novocure To Present INNOVATE-3 Phase 3 Pivotal Trial Design In Recurrent Ovarian Cancer At The American Society Of Clinical Oncology Annual Meeting 2018

Novocure To Present INNOVATE-3 Phase 3 Pivotal Trial Design In Recurrent Ovarian Cancer At The American Society Of Clinical Oncology Annual Meeting 2018

Novocure (NASDAQ: NVCR) will present today for the first time the design of its phase 3 pivotal trial of Tumor Treating Fields combined with paclitaxel in patients with recurrent, platinum-resistant ovarian cancer at the American Society of Clinical...

Novocure Reports First Quarter 2018 Financial Results And Provides Company Update

Novocure Reports First Quarter 2018 Financial Results And Provides Company Update

Novocure (NASDAQ: NVCR) today reported financial results for the quarter and year ended March 31, 2018, highlighting year-over-year growth in active patients and net revenues.

Novocure To Report First Quarter 2018 Financial Results

Novocure To Report First Quarter 2018 Financial Results

Novocure (NASDAQ: NVCR) announced today that it will report financial results for the first quarter 2018 on Thursday, April 26, 2018, before the U.

First Week of NVCR May 18th Options Trading

First Week of NVCR May 18th Options Trading

Investors in NovoCure Ltd saw new options begin trading this week, for the May 18th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the NVCR options chain for the new May 18th contracts and identified one put and one call contract of particular interest.

NCCN Guidelines Recommend Optune In Combination With Temozolomide As A Category 1 Treatment For Newly Diagnosed Glioblastoma

NCCN Guidelines Recommend Optune In Combination With Temozolomide As A Category 1 Treatment For Newly Diagnosed Glioblastoma

Novocure (NASDAQ: NVCR) announced today that the National Comprehensive Cancer Network (NCCN) has updated its clinical practice guidelines to recommend Optune® in combination with temozolomide as a category 1 treatment...

Novocure Announces 35 Presentations On Tumor Treating Fields At The American Association For Cancer Research Annual Meeting 2018

Novocure Announces 35 Presentations On Tumor Treating Fields At The American Association For Cancer Research Annual Meeting 2018

Novocure (NASDAQ: NVCR) announced today 35 presentations on Tumor Treating Fields at the American Association for Cancer Research (AACR) Annual Meeting 2018, April 14 through April 18, in Chicago.

Big Earnings Week Ahead: Cramer's 'Mad Money' Recap (Monday 2/26/18)

Big Earnings Week Ahead: Cramer's 'Mad Money' Recap (Monday 2/26/18)

Jim Cramer is keeping a close eye on retail earnings this week, along with testimony from new Fed Chair Jerome Powell.

Novocure Reports Fourth Quarter And Full Year 2017 Financial Results And Provides Company Update

Novocure Reports Fourth Quarter And Full Year 2017 Financial Results And Provides Company Update

Novocure (NASDAQ: NVCR) today reported financial results for the quarter and year ended December 31, 2017, highlighting year-over-year and sequential growth in active patients and net revenues.

Novocure Secures New $150 Million Non-Dilutive Term Loan Financing

Novocure Secures New $150 Million Non-Dilutive Term Loan Financing

Novocure (NASDAQ: NVCR) announced today that it has entered into a $150 million term loan agreement with BioPharma Credit PLC (LSE: BPCR), an investment fund managed by Pharmakon Advisors, LP, with proceeds used to pay in...

JAMA Oncology Publishes EF-14 Pivotal Trial Analysis Showing Optune Plus Temozolomide Improved Survival Without Negatively Influencing Health-Related Quality Of Life Compared To Temozolomide Alone In Newly Diagnosed GBM Patients

JAMA Oncology Publishes EF-14 Pivotal Trial Analysis Showing Optune Plus Temozolomide Improved Survival Without Negatively Influencing Health-Related Quality Of Life Compared To Temozolomide Alone In Newly Diagnosed GBM Patients

Novocure (NASDAQ: NVCR) announced today that a detailed quality of life analysis of Novocure's EF-14 phase 3 pivotal trial of Optune in combination with temozolomide for the treatment of newly diagnosed glioblastoma (GBM)...

TheStreet Quant Rating: D (Sell)